AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comSEP 42 min read$RXRX

Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report?

Recursion Pharmaceuticals (RXRX) shares rose 8.2% since last earnings report, outperforming the S&P 500. Q2 2026 earnings showed a loss of 25 cents per share, wider than estimates, with revenues falling 60% YoY to $7.67M. Operating costs decreased, and cash reserves are expected to last into early 2028. Analyst estimates have shifted 6.51% in the past month.

Original reporting
finance.yahoo.com
Published Sep 4, 2026, 3:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 6, 2026, 1:21 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$RXRX
Bearish
medium confidence
Mentioned
$RXRX
Relevance
4/10
AlphAI data visualization · based on finance.yahoo.com
Decision brief

The 30-second read

$RXRXBearishLow
01

Why it matters

The earnings miss reinforces bearish sentiment; investors may target the stock for short positions.

02

Market read

Earnings disappointment adds pressure to a micro‑cap biotech already under scrutiny.

03

What to watch

Grant revenue growth and cost reductions may improve margins over time.

Relevance 4/10Novelty 2/10Timing: post‑earnings month

Background

Recursion Pharmaceuticals' latest quarterly results show a deeper loss and steep revenue decline, with cash sufficient through early 2028.

Company-level read

Ticker impact

$RXRXBearishMedium confidence
Context

Q2 2026 earnings miss: loss of $0.25/share, revenue down 60% to $7.67M, cash $556.8M

Expected impact

Potential short-term downside as investors reassess cash runway.

Evidence & confidence

Loss widened versus consensus and revenue fell sharply; no new guidance provided.

Market effects

Sector

Biotech sector may see broader caution after another revenue miss.

Regional

Limited to US biotech investors.

Global

Low global impact.

Counterpoint

What could challenge this read

Cash runway to 2028 could support a rebound if pipeline milestones are hit.

Key entities

  • Company
    Recursion Pharmaceuticals

    NASDAQ‑listed biotech focused on AI‑driven drug discovery.

Read at source← All news

Related articles

SEP 4
$RXRXMed

RXRX Stock Steadies As AI Drug Engine Tightens Spending

Recursion Pharmaceuticals (RXRX) shares rose 5.81% on AI-driven drug discovery progress. The company reported $74.3M revenue, negative margins, and $545M in cash. Genentech optioned a neuroscience target, and RXRX cut FY26 spending to $375M, extending cash runway to early 2028. Analysts have mixed views, with an average price target of $7.22.

stockstotrade.com3 min
SEP 4
$RXRXMed

RXRX Tightens Cash Burn As AI Drug Pipeline Advances

Recursion Pharmaceuticals (RXRX) stock rose 5.96% on September 4, 2026, to $3.64, driven by AI drug discovery advancements. The company reported Q2 2026 revenue of $7.3M, a net loss of $131M, and $545M in cash. RXRX reduced its FY26 expense guidance to $375M, reflecting tighter cost management. Analysts' average price target is $7.22, with tangible clinical and partnership catalysts on the horizon.

stockstotrade.com4 min
SEP 4
$RXRXMed

RXRX Tightens Costs As AI Drug Pipeline Advances

Recursion Pharmaceuticals Inc. (RXRX) stock rose 5.83% on positive AI drug discovery progress. The company reported Q2 revenue of $74.3M, negative margins, and cash burn of -$106M, but has $545.7M in cash. RXRX guided 2026 cash operating expenses to $375M, down 40% from 2024. Analysts have mixed views, with Morgan Stanley trimming its target to $5.30 but the Street's average at $7.22.

timothysykes.com2 min
AUG 25
$RXRXMed

RXRX Stock Rallies As AI Drug Platform Tightens Cash Burn

Recursion Pharmaceuticals (RXRX) stock rose 7.23% on August 25, 2026, driven by AI-driven drug discovery progress. The company reported Q2 revenue of $7.7M, a net loss of $131M, and holds $545.7M in cash. Analysts have mixed views, with a mean price target of $7.22. RXRX is advancing its pipeline and cut FY26 cash burn guidance to $375M, extending its runway into early 2028.

stockstotrade.com3 min